Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc.

Overview
Date Founded

2011

Headquarters

171 Oyster Point Boulevard,Suite 300,South San Francisco, CA 94080

Type of Company

Public

Employees (Worldwide)

171

Industries

Pharmaceuticals
Medical Support Services
Holding Companies
Biotechnology

Company Description

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Global Blood Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Chief Commercial Officer

Chief Scientific Officer

Chief Accounting Officer & Senior Vice President-Finance

Chief Legal Officer

Chief Business & Strategy Officer

Chief Medical Officer

Chief Human Resources Officer

Senior Vice President, Head of Medical Affairs & Program Team Leader, Voxelotor

Board of Directors

Former Chief Financial Officer at Gilead Sciences, Inc.

Founding Director at Stanford Distinguished Careers Institute

President & Chief Executive Officer at Global Blood Therapeutics, Inc.

Chairman & Chief Executive Officer at San Francisco State University - The Willie L. Brown, Jr. Institute of Politics & Public Service

Former President-Europe & Canada Region at Merck & Co., Inc.

Former Senior Vice President, Human Resources at Merck & Co., Inc.

Director & Treasurer at The Biotechnology Institute

Chief Medical Officer & Senior Vice President at Bioverativ Therapeutics, Inc.

Paths to Global Blood Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Global Blood Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. Perceptive Advisors advises two separate master-feeder private fund structures.The Perceptive Life Sciences Funds invest in the equities of growth healthcare companies and value plays, with an emphasis on biotechnology. Perceptive Advisors seeks to identify opportunities to exploit relative value disparities and inefficiencies that exist on both the long and short side of the market. They focus on a universe of about 300 smaller, more inefficiently priced companies which are underfollowed by Wall Street biotechnology analysts. Hedging strategies using long and short equity positions, equity options, and index options are used in an attempt to reduce and control risk.The Perceptive Credit Opportunity Fund seeks to achieve superior risk-adjusted returns by investing in senior secured loans and other debt and debt-related instruments issued by small- and mid-cap publicly traded companies and privately-held emerging growth companies primarily in the healthcare and related industries. The fund's investments may be originated by the fund or in collaboration with a syndicate of other credit investors. Most of the fund's investments will be structured as directly originated loans to healthcare companies.Perceptive Advisors also advises two separate accounts. The investment strategies of the separate accounts are substantially similar to those of the Perceptive Life Sciences Fund, though the separate accounts may take more concentrated positions and use a higher degree of leverage.

Details Hidden

BofA Securities, Inc., a subsidiary of Bank of America Corp., is a company headquartered in New York, NY. The firm provides brokerage services. It was founded in 2015. Thomas Kell Montag is the current CEO, occupying that position since 2018.

Details Hidden

FCM seeks to achieve superior risk-adjusted rates of return through a process of fundamental analysis that emphasizes capital preservation. The firm uses the following sources: a variety of publicly available information sources, including but not limited to financial periodicals, corporate rating services, annual reports, prospectuses and filings with the SEC and other regulators, company press releases, as well as, and to the extent applicable or appropriate, information provided by management and creditors of portfolio companies, brokers, dealers, analysts, professional asset managers, research services and hired consultants and advisers. Historically, FCM's core strategies have included merger arbitrage, credit investments, real estate investments, direct investments and long/short equity. They make investments in public and private debt and equity securities, as well as direct investments in private companies and real estate.

Recent Transactions
Details Hidden

Global Blood Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Global Blood Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Global Blood Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onGlobal Blood Therapeutics, Inc. issued . USD Common Stock

Escrow Agent

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Head of Investment Banking

Advised onGlobal Blood Therapeutics, Inc. issued . USD Common Stock

Director

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Senior Advisor

Former Head-Drug Discovery at Incyte Corp.

Publicist

Executive Vice President at Vida Strategic Partners, Inc.

Key Stats and Financials As of 2018
Market Capitalization
$4.26B
Total Enterprise Value
$1.62B
Earnings Per Share
$-3.41
Revenue
$0
Net Profit
$-174M
Total Equity
$573M
TEVNet Income
-9.31x
Debt TEV
0x
Total Debt
$0
EBITDA
$-178M
Investors
Details Hidden

Deerfield Management Co. LP (Private Equity) invests in a broad range of industries. It provides financing for buyout transactions to private and public companies located in the U.S.

Details Hidden

Partner & Chief Technology Officer at Third Rock Ventures LLC

Details Hidden

Perceptive Advisors invests in health care technology companies located in the US. The firm provides financing for early stage requirements and their AUM is $3 billion.

Suppliers
University of California Investment Services & Portfolio Management | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Roche Holding AG Medical Support Services | Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Global Blood Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Global Blood Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Global Blood Therapeutics, Inc..